Teva Pharmaceuticals (TEVA) launches first U.S. generic version of Sandostatin LAR, an antidiarrheal marketed by Novartis ...

which Teva predicts will bring in $2.5 billion in sales in 2027, fuelled by growth of a new once-daily formulation. That’s a sizeable increase on Teva’s projections of around $1.2 billion for ...

This first-to-market launch showcases Teva’s proven strengths in complex generic formulations and enhances Teva’s strategic ...

A New Jersey federal judge has approved a $2.7 million settlement resolving claims from a group of sales specialists who ...

Shares of Teva Pharmaceutical Industries TEVA on Tuesday the launch of the first and only generic version of Sandostatin LAR ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 72.5% so far this year compared with an increase of 17.9% for ...

Though Teva is seeing slower growth of Ajovy in the U.S. market, it expects sales to benefit from continued patient growth and launches in additional countries in Europe and international markets.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced the launch of the first and only generic ...

That's a much larger increase than $208 million and would represent a 7% increase over the firm's sales last quarter. The Demand for Teva's Generic and Branded Drugs Should Remain Strong In ...

Teva Pharmaceuticals USA Inc. has made an “arms-length settlement” for $2.7 million to resolve claims that the Israeli pharmaceutical giant misclassified sales specialists as salary-exempt trainees ...